These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

433 related articles for article (PubMed ID: 26314962)

  • 1. Targeting the mRNA-binding protein HuR impairs malignant characteristics of pancreatic ductal adenocarcinoma cells.
    Jimbo M; Blanco FF; Huang YH; Telonis AG; Screnci BA; Cosma GL; Alexeev V; Gonye GE; Yeo CJ; Sawicki JA; Winter JM; Brody JR
    Oncotarget; 2015 Sep; 6(29):27312-31. PubMed ID: 26314962
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HuR Contributes to TRAIL Resistance by Restricting Death Receptor 4 Expression in Pancreatic Cancer Cells.
    Romeo C; Weber MC; Zarei M; DeCicco D; Chand SN; Lobo AD; Winter JM; Sawicki JA; Sachs JN; Meisner-Kober N; Yeo CJ; Vadigepalli R; Tykocinski ML; Brody JR
    Mol Cancer Res; 2016 Jul; 14(7):599-611. PubMed ID: 27053682
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HuR mediated post-transcriptional regulation as a new potential adjuvant therapeutic target in chemotherapy for pancreatic cancer.
    Jakstaite A; Maziukiene A; Silkuniene G; Kmieliute K; Gulbinas A; Dambrauskas Z
    World J Gastroenterol; 2015 Dec; 21(46):13004-19. PubMed ID: 26675757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Posttranscriptional Regulation of
    Chand SN; Zarei M; Schiewer MJ; Kamath AR; Romeo C; Lal S; Cozzitorto JA; Nevler A; Scolaro L; Londin E; Jiang W; Meisner-Kober N; Pishvaian MJ; Knudsen KE; Yeo CJ; Pascal JM; Winter JM; Brody JR
    Cancer Res; 2017 Sep; 77(18):5011-5025. PubMed ID: 28687616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human antigen R mediated post-transcriptional regulation of inhibitors of apoptosis proteins in pancreatic cancer.
    Lukosiute-Urboniene A; Jasukaitiene A; Silkuniene G; Barauskas V; Gulbinas A; Dambrauskas Z
    World J Gastroenterol; 2019 Jan; 25(2):205-219. PubMed ID: 30670910
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HuR's post-transcriptional regulation of Death Receptor 5 in pancreatic cancer cells.
    Pineda DM; Rittenhouse DW; Valley CC; Cozzitorto JA; Burkhart RA; Leiby B; Winter JM; Weber MC; Londin ER; Rigoutsos I; Yeo CJ; Gorospe M; Witkiewicz AK; Sachs JN; Brody JR
    Cancer Biol Ther; 2012 Aug; 13(10):946-55. PubMed ID: 22785201
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HuR posttranscriptionally regulates WEE1: implications for the DNA damage response in pancreatic cancer cells.
    Lal S; Burkhart RA; Beeharry N; Bhattacharjee V; Londin ER; Cozzitorto JA; Romeo C; Jimbo M; Norris ZA; Yeo CJ; Sawicki JA; Winter JM; Rigoutsos I; Yen TJ; Brody JR
    Cancer Res; 2014 Feb; 74(4):1128-40. PubMed ID: 24536047
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The mRNA-binding protein HuR promotes hypoxia-induced chemoresistance through posttranscriptional regulation of the proto-oncogene PIM1 in pancreatic cancer cells.
    Blanco FF; Jimbo M; Wulfkuhle J; Gallagher I; Deng J; Enyenihi L; Meisner-Kober N; Londin E; Rigoutsos I; Sawicki JA; Risbud MV; Witkiewicz AK; McCue PA; Jiang W; Rui H; Yeo CJ; Petricoin E; Winter JM; Brody JR
    Oncogene; 2016 May; 35(19):2529-41. PubMed ID: 26387536
    [TBL] [Abstract][Full Text] [Related]  

  • 9. dCK expression correlates with 5-fluorouracil efficacy and HuR cytoplasmic expression in pancreatic cancer: a dual-institutional follow-up with the RTOG 9704 trial.
    McAllister F; Pineda DM; Jimbo M; Lal S; Burkhart RA; Moughan J; Winter KA; Abdelmohsen K; Gorospe M; Acosta Ade J; Lankapalli RH; Winter JM; Yeo CJ; Witkiewicz AK; Iacobuzio-Donahue CA; Laheru D; Brody JR
    Cancer Biol Ther; 2014 Jun; 15(6):688-98. PubMed ID: 24618665
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Delivery of Therapeutics Targeting the mRNA-Binding Protein HuR Using 3DNA Nanocarriers Suppresses Ovarian Tumor Growth.
    Huang YH; Peng W; Furuuchi N; Gerhart J; Rhodes K; Mukherjee N; Jimbo M; Gonye GE; Brody JR; Getts RC; Sawicki JA
    Cancer Res; 2016 Mar; 76(6):1549-59. PubMed ID: 26921342
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HuR status is a powerful marker for prognosis and response to gemcitabine-based chemotherapy for resected pancreatic ductal adenocarcinoma patients.
    Richards NG; Rittenhouse DW; Freydin B; Cozzitorto JA; Grenda D; Rui H; Gonye G; Kennedy EP; Yeo CJ; Brody JR; Witkiewicz AK
    Ann Surg; 2010 Sep; 252(3):499-505; discussion 505-6. PubMed ID: 20739850
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytoplasmic HuR Status Predicts Disease-free Survival in Resected Pancreatic Cancer: A Post-hoc Analysis From the International Phase III ESPAC-3 Clinical Trial.
    Tatarian T; Jiang W; Leiby BE; Grigoli A; Jimbo M; Dabbish N; Neoptolemos JP; Greenhalf W; Costello E; Ghaneh P; Halloran C; Palmer D; Buchler M; Yeo CJ; Winter JM; Brody JR
    Ann Surg; 2018 Feb; 267(2):364-369. PubMed ID: 27893535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GPRC5A is a potential oncogene in pancreatic ductal adenocarcinoma cells that is upregulated by gemcitabine with help from HuR.
    Zhou H; Telonis AG; Jing Y; Xia NL; Biederman L; Jimbo M; Blanco F; Londin E; Brody JR; Rigoutsos I
    Cell Death Dis; 2016 Jul; 7(7):e2294. PubMed ID: 27415424
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elevated HuR in Pancreas Promotes a Pancreatitis-Like Inflammatory Microenvironment That Facilitates Tumor Development.
    Peng W; Furuuchi N; Aslanukova L; Huang YH; Brown SZ; Jiang W; Addya S; Vishwakarma V; Peters E; Brody JR; Dixon DA; Sawicki JA
    Mol Cell Biol; 2018 Feb; 38(3):. PubMed ID: 29133460
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CRISPR Knockout of the HuR Gene Causes a Xenograft Lethal Phenotype.
    Lal S; Cheung EC; Zarei M; Preet R; Chand SN; Mambelli-Lisboa NC; Romeo C; Stout MC; Londin E; Goetz A; Lowder CY; Nevler A; Yeo CJ; Campbell PM; Winter JM; Dixon DA; Brody JR
    Mol Cancer Res; 2017 Jun; 15(6):696-707. PubMed ID: 28242812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of HuR inhibition by the small molecule MS-444 on colorectal cancer cell tumorigenesis.
    Blanco FF; Preet R; Aguado A; Vishwakarma V; Stevens LE; Vyas A; Padhye S; Xu L; Weir SJ; Anant S; Meisner-Kober N; Brody JR; Dixon DA
    Oncotarget; 2016 Nov; 7(45):74043-74058. PubMed ID: 27677075
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overexpressed EDIL3 predicts poor prognosis and promotes anchorage-independent tumor growth in human pancreatic cancer.
    Jiang SH; Wang Y; Yang JY; Li J; Feng MX; Wang YH; Yang XM; He P; Tian GA; Zhang XX; Li Q; Cao XY; Huo YM; Yang MW; Fu XL; Li J; Liu DJ; Dai M; Wen SY; Gu JR; Hong J; Hua R; Zhang ZG; Sun YW
    Oncotarget; 2016 Jan; 7(4):4226-40. PubMed ID: 26735172
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Understanding and targeting the disease-related RNA binding protein human antigen R (HuR).
    Schultz CW; Preet R; Dhir T; Dixon DA; Brody JR
    Wiley Interdiscip Rev RNA; 2020 May; 11(3):e1581. PubMed ID: 31970930
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor-targeted Nanoparticle Delivery of HuR siRNA Inhibits Lung Tumor Growth
    Muralidharan R; Babu A; Amreddy N; Srivastava A; Chen A; Zhao YD; Kompella UB; Munshi A; Ramesh R
    Mol Cancer Ther; 2017 Aug; 16(8):1470-1486. PubMed ID: 28572169
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HuR is a post-transcriptional regulator of core metabolic enzymes in pancreatic cancer.
    Burkhart RA; Pineda DM; Chand SN; Romeo C; Londin ER; Karoly ED; Cozzitorto JA; Rigoutsos I; Yeo CJ; Brody JR; Winter JM
    RNA Biol; 2013 Aug; 10(8):1312-23. PubMed ID: 23807417
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.